Achillion Pharmaceuticals Inc (ACHN) - Financial and Strategic SWOT Analysis Review
Achillion Pharmaceuticals Inc (ACHN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system related disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD). Achillion is headquartered in New Haven, Connecticut, the US.
Achillion Pharmaceuticals Inc Key Recent Developments
Aug 08,2019: Achillion reports second quarter 2019 financial results and provides corporate update
May 09,2019: Achillion reports first quarter 2019 financial results
Mar 07,2019: Achillion reports fourth quarter and full year 2018 financial results
Feb 21,2019: Achillion Pharmaceuticals expands pperations and clinical development into Philadelphia area office market
Feb 11,2019: Achillion Pharmaceuticals names Brian Di Donato as Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Achillion Pharmaceuticals Inc (Achillion) is a biopharmaceutical company which focuses on the discovery and development of small molecule therapeutic products for treatment of infectious diseases and immune system related disorders. The company focuses at developing life-saving medicines to patients with rare diseases. It is developing oral antiviral therapy for chronic hepatitis C (HCV) and a platform of potent and specific complement inhibitors. Achillion intends to develop and commercialize factor D inhibitors for rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD). Achillion is headquartered in New Haven, Connecticut, the US.
Achillion Pharmaceuticals Inc Key Recent Developments
Aug 08,2019: Achillion reports second quarter 2019 financial results and provides corporate update
May 09,2019: Achillion reports first quarter 2019 financial results
Mar 07,2019: Achillion reports fourth quarter and full year 2018 financial results
Feb 21,2019: Achillion Pharmaceuticals expands pperations and clinical development into Philadelphia area office market
Feb 11,2019: Achillion Pharmaceuticals names Brian Di Donato as Chief Financial Officer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Achillion Pharmaceuticals Inc - Key Facts
Achillion Pharmaceuticals Inc - Key Employees
Achillion Pharmaceuticals Inc - Key Employee Biographies
Achillion Pharmaceuticals Inc - Major Products and Services
Achillion Pharmaceuticals Inc - History
Achillion Pharmaceuticals Inc - Company Statement
Achillion Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Achillion Pharmaceuticals Inc - Business Description
R&D Overview
Achillion Pharmaceuticals Inc - Corporate Strategy
Achillion Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Achillion Pharmaceuticals Inc - Strengths
Achillion Pharmaceuticals Inc - Weaknesses
Achillion Pharmaceuticals Inc - Opportunities
Achillion Pharmaceuticals Inc - Threats
Achillion Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 08, 2019: Achillion reports second quarter 2019 financial results and provides corporate update
May 09, 2019: Achillion reports first quarter 2019 financial results
Mar 07, 2019: Achillion reports fourth quarter and full year 2018 financial results
Feb 21, 2019: Achillion Pharmaceuticals expands pperations and clinical development into Philadelphia area office market
Feb 11, 2019: Achillion Pharmaceuticals names Brian Di Donato as Chief Financial Officer
Jan 03, 2019: Achillion announces Nicole Vitullo elected to Chair the Board of Directors
Dec 10, 2018: Achillion interim clinical trial data and strategic update planned for Dec 17th, 2018
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Achillion Pharmaceuticals Inc - Key Facts
Achillion Pharmaceuticals Inc - Key Employees
Achillion Pharmaceuticals Inc - Key Employee Biographies
Achillion Pharmaceuticals Inc - Major Products and Services
Achillion Pharmaceuticals Inc - History
Achillion Pharmaceuticals Inc - Company Statement
Achillion Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Achillion Pharmaceuticals Inc - Business Description
R&D Overview
Achillion Pharmaceuticals Inc - Corporate Strategy
Achillion Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Achillion Pharmaceuticals Inc - Strengths
Achillion Pharmaceuticals Inc - Weaknesses
Achillion Pharmaceuticals Inc - Opportunities
Achillion Pharmaceuticals Inc - Threats
Achillion Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 08, 2019: Achillion reports second quarter 2019 financial results and provides corporate update
May 09, 2019: Achillion reports first quarter 2019 financial results
Mar 07, 2019: Achillion reports fourth quarter and full year 2018 financial results
Feb 21, 2019: Achillion Pharmaceuticals expands pperations and clinical development into Philadelphia area office market
Feb 11, 2019: Achillion Pharmaceuticals names Brian Di Donato as Chief Financial Officer
Jan 03, 2019: Achillion announces Nicole Vitullo elected to Chair the Board of Directors
Dec 10, 2018: Achillion interim clinical trial data and strategic update planned for Dec 17th, 2018
Sep 10, 2018: Achillion Pharmaceuticals names Paul Firuta Chief Operating Officer
Aug 21, 2018: Achillion Pharmaceuticals names Dr. Steven Zelenkofske as Chief Medical Officer
Aug 15, 2018: Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Achillion Pharmaceuticals Inc, Key Facts
Achillion Pharmaceuticals Inc, Key Employees
Achillion Pharmaceuticals Inc, Key Employee Biographies
Achillion Pharmaceuticals Inc, Major Products and Services
Achillion Pharmaceuticals Inc, History
Achillion Pharmaceuticals Inc, Other Locations
Achillion Pharmaceuticals Inc, Key Competitors
Achillion Pharmaceuticals Inc, Ratios based on current share price
Achillion Pharmaceuticals Inc, Annual Ratios
Achillion Pharmaceuticals Inc, Annual Ratios (Cont...1)
Achillion Pharmaceuticals Inc, Interim Ratios
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Achillion Pharmaceuticals Inc, Key Facts
Achillion Pharmaceuticals Inc, Key Employees
Achillion Pharmaceuticals Inc, Key Employee Biographies
Achillion Pharmaceuticals Inc, Major Products and Services
Achillion Pharmaceuticals Inc, History
Achillion Pharmaceuticals Inc, Other Locations
Achillion Pharmaceuticals Inc, Key Competitors
Achillion Pharmaceuticals Inc, Ratios based on current share price
Achillion Pharmaceuticals Inc, Annual Ratios
Achillion Pharmaceuticals Inc, Annual Ratios (Cont...1)
Achillion Pharmaceuticals Inc, Interim Ratios
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Achillion Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Achillion Pharmaceuticals Inc, Ratio Charts
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
Regeneron Pharmaceuticals Inc
Ra Pharmaceuticals, Inc.
Omeros Corporation
Novartis AG
ChemoCentryx, Inc
Amyndas Pharmaceuticals LLC
Amgen Inc
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc
Achillion Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Achillion Pharmaceuticals Inc, Ratio Charts
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Achillion Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
COMPANIES MENTIONED
Regeneron Pharmaceuticals Inc
Ra Pharmaceuticals, Inc.
Omeros Corporation
Novartis AG
ChemoCentryx, Inc
Amyndas Pharmaceuticals LLC
Amgen Inc
Alexion Pharmaceuticals Inc
Akari Therapeutics Plc